SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences (NASDAQ: SLS) reported Q2 2025 financial results and significant progress in its AML-focused pipeline. The company's Phase 3 REGAL trial of GPS received a positive IDMC recommendation to continue without modification, with final analysis expected by year-end 2025.
Their Phase 2 trial of SLS009 in r/r AML achieved impressive results, with a 44% response rate in AML-MRC patients and median overall survival of 8.9 months, significantly exceeding historical benchmarks. The FDA has recommended advancing SLS009 to first-line AML treatment, with an 80-patient trial expected to begin by Q1 2026.
Financially, SELLAS reported a Q2 2025 net loss of $6.6 million ($0.07 per share), with $25.3 million in cash as of June 30, 2025, plus an additional $4.0 million from warrant exercises in July 2025.
SELLAS Life Sciences (NASDAQ: SLS) ha reso noti i risultati finanziari del secondo trimestre 2025 e ha segnalato progressi significativi nel suo programma focalizzato sull'AML. Lo studio di fase 3 REGAL su GPS ha ricevuto una raccomandazione favorevole dall'IDMC di proseguire senza modifiche; l'analisi finale è prevista entro la fine del 2025.
Lo studio di fase 2 su SLS009 in pazienti con AML recidivante/refrattaria (r/r) ha ottenuto risultati notevoli, con un tasso di risposta del 44% nei pazienti con AML‑MRC e una sopravvivenza mediana globale di 8,9 mesi, superando nettamente i benchmark storici. La FDA ha raccomandato di avanzare SLS009 come terapia di prima linea per l'AML; uno studio su 80 pazienti è previsto per partire entro il primo trimestre 2026.
Sul piano finanziario, SELLAS ha riportato una perdita netta nel Q2 2025 di $6,6 milioni (pari a $0,07 per azione), con $25,3 milioni in cassa al 30 giugno 2025 e ulteriori $4,0 milioni derivanti dall'esercizio di warrant a luglio 2025.
SELLAS Life Sciences (NASDAQ: SLS) informó resultados financieros del segundo trimestre de 2025 y avances significativos en su cartera centrada en AML. El ensayo de fase 3 REGAL de GPS recibió una recomendación favorable del IDMC para continuar sin modificaciones; el análisis final se espera para finales de 2025.
Su ensayo de fase 2 de SLS009 en AML refractaria/relapsada (r/r) obtuvo resultados impresionantes, con una tasa de respuesta del 44% en pacientes con AML‑MRC y una supervivencia global mediana de 8,9 meses, superando notablemente los referentes históricos. La FDA ha recomendado avanzar SLS009 como tratamiento de primera línea para AML; se espera iniciar un ensayo de 80 pacientes antes del primer trimestre de 2026.
En lo financiero, SELLAS registró una pérdida neta en el Q2 2025 de $6,6 millones ( $0,07 por acción), con $25,3 millones en efectivo al 30 de junio de 2025, más $4,0 millones adicionales procedentes de la ejecución de warrants en julio de 2025.
SELLAS Life Sciences (NASDAQ: SLS)� 2025� 2분기 실적� AML 중심 파이프라인에서의 중요� 진전� 발표했습니다. GPS� 대� 3� REGAL 시험은 IDMC로부� 변� 없이 계속하라� 긍정� 권고� 받았으며, 최종 분석은 2025� 말까지 예정되어 있습니다.
SLS009� 재발/불응(r/r) AML 대� 2� 시험은 AML‑MRC 환자에서 44% 반응�� 중앙 전체생존기간 8.9개월� 달성� 과거 기준� 크게 상회했습니다. FDA� SLS009� AML� 1� 치료제로 진전시키도록 권고했으�, 80� 규모� 시험� 2026� 1분기까지 시작� 것으� 예상됩니�.
재무적으� SELLAS� 2025� 2분기 순손� $6.6 million (주당 $0.07)� 보고했으�, 2025� 6� 30� 기준 현금 $25.3 million� 보유하고 있고, 2025� 7� 워런� 행사� 추가 $4.0 million� 확보했습니다.
SELLAS Life Sciences (NASDAQ: SLS) a publié ses résultats financiers du deuxième trimestre 2025 et annoncé des progrès significatifs dans sa filière axée sur l'AML. L'essai de phase 3 REGAL du GPS a reçu une recommandation positive de l'IDMC pour se poursuivre sans modification ; l'analyse finale est attendue d'ici la fin 2025.
Son essai de phase 2 de SLS009 dans l'AML récurrente/réfractaire (r/r) a obtenu des résultats impressionnants, avec un taux de réponse de 44% chez les patients atteints d'AML‑MRC et une survie globale médiane de 8,9 mois, dépassant nettement les références historiques. La FDA a recommandé d'avancer SLS009 en première ligne contre l'AML ; un essai de 80 patients devrait débuter d'ici le premier trimestre 2026.
Sur le plan financier, SELLAS a enregistré une perte nette au T2 2025 de $6,6 millions (soit $0,07 par action), disposait de $25,3 millions de trésorerie au 30 juin 2025 et a obtenu $4,0 millions supplémentaires suite à l'exercice de warrants en juillet 2025.
SELLAS Life Sciences (NASDAQ: SLS) veröffentlichte die Finanzergebnisse für das zweite Quartal 2025 und meldete bedeutende Fortschritte in seiner AML‑fokussierten Pipeline. Die Phase�3‑Studie REGAL von GPS erhielt eine positive Empfehlung des IDMC, ohne Änderungen fortzufahren; die Abschlusanalyse wird bis Ende 2025 erwartet.
Die Phase�2‑Studie von SLS009 in rezidivierter/refraktärer AML (r/r) erzielte beeindruckende Ergebnisse: eine Ansprechrate von 44% bei Patienten mit AML‑MRC und ein medianes Gesamtüberleben von 8,9 Monaten, womit historische Vergleichswerte deutlich übertroffen wurden. Die FDA hat empfohlen, SLS009 in die Erstlinientherapie der AML vorzuziehen; eine Studie mit 80 Patienten soll bis zum ersten Quartal 2026 starten.
Finanziell berichtete SELLAS einen Nettoverlust im Q2 2025 von $6,6 Millionen ( $0,07 je Aktie) und verfügte zum 30. Juni 2025 über $25,3 Millionen an liquiden Mitteln, zuzüglich weiterer $4,0 Millionen aus der Ausübung von Warrants im Juli 2025.
- Phase 2 trial of SLS009 achieved 44% response rate in AML-MRC, significantly exceeding 20% target
- Median overall survival of 8.9 months in AML-MRC patients, far surpassing 2.4-month historical benchmark
- Positive IDMC recommendation for Phase 3 REGAL trial continuation
- FDA support to advance SLS009 to first-line AML treatment
- Net loss per share decreased to $0.07 in Q2 2025 from $0.13 in Q2 2024
- R&D expenses decreased to $3.9M from $5.2M year-over-year
- Strong cash position of $29.3M including July warrant exercises
- General and administrative expenses increased by $0.6M year-over-year in Q2
- Continued net losses of $6.6M in Q2 2025
- Additional clinical trials and regulatory processes required before potential commercialization
Insights
SELLAS reports strong clinical progress with two AML therapies showing positive results and FDA alignment for new trials with $29.3M cash position.
SELLAS Life Sciences continues to demonstrate significant clinical momentum across their pipeline focused on acute myeloid leukemia (AML). The company received a positive recommendation from the Independent Data Monitoring Committee to continue their pivotal Phase 3 REGAL trial of Galinpepimut-S (GPS) without modifications, with final analysis expected by year-end 2025.
More impressively, their novel CDK9 inhibitor SLS009 achieved remarkable efficacy in Phase 2 trials for relapsed/refractory AML, with a
Following these compelling results, the FDA has recommended advancing SLS009 into first-line AML treatment. The planned 80-patient randomized trial will target two critical populations: newly diagnosed patients with poor molecular profiles unlikely to respond to standard venetoclax/azacitidine therapy, and those showing early resistance after two treatment cycles. This strategic trial design could potentially support an accelerated approval pathway.
Their financial position appears stable with
- Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 �
-Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) with Trial Meeting All Primary Endpoints; Full Data Presentation Expected Later This Year -
-Alignment with FDA to Advance SLS009 in a First-Line AML Trial with Enrollment Anticipated by Q1 2026 -
-
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’� or the “Company�), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
“We continue to make significant progress in advancing our AML-focused pipeline, as demonstrated by the positive Phase 2 results evaluating our novel CDK9 inhibitor, SLS009, for the treatment of r/r AML,� said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “The Phase 2 trial met all primary endpoints, achieving a
Dr. Stergiou continued, “During the quarter, we also presented promising preclinical data at ASCO supporting SLS009 as a potential targeted therapy for ASXL1 mutated colorectal cancer and strengthened our scientific leadership with the addition of three world-class oncology experts to our Scientific Advisory Board. With the final pivotal Phase 3 REGAL data of GPS in AML expected by year-end, positive Phase 2 data of SLS009 in r/r AML, and our upcoming ESMO presentation showcasing SLS009’s impact in T-PLL, we enter the second half of 2025 with tremendous momentum and a clear focus on advancing our late-stage clinical programs and growing shareholder value.�
Recent Corporate Highlights:
Phase 3 REGAL Trial of GPS: On August 7, 2025, SELLAS announced that the IDMC completed a pre-specified analysis of the Phase 3 REGAL trial of GPS in AML and issued a positive recommendation to continue the trial without modification. The IDMC concluded that the risk-benefit profile of GPS supports continued evaluation under the current study protocol. No safety concerns were identified, and available efficacy data were consistent with expectations for continued trial conduct. The final analysis will be conducted once 80 events (deaths) are reached and is anticipated by year-end.
Announced Positive Results from Phase 2 Trial of SLS009 in r/r AML: The trial met all primary endpoints, demonstrating a
SLS009 End-of-Phase 2 Meeting: The FDA recommended that SELLAS proceed into a trial to include newly diagnosed, first-line AML patients eligible for venetoclax/azacitidine (aza/ven) therapy, where the Agency believes clinical benefit might be greatest. The randomized 80-patient trial is currently in preparation and is expected to begin enrollment by Q1 2026. The FDA indicated a preference for response rate as the primary endpoint. The trial will include two groups: 1) predictive biomarker cohort of newly diagnosed patients unlikely to benefit from standard aza/ven therapy based on molecular profiling, and 2) early resistance cohort of patients who initiate treatment with aza/ven but demonstrate confirmed lack of any response after two treatment cycles. Whether additional patients will be needed � either for broader study expansion or only within one of the study arms � will depend on the outcomes observed in the initial cohorts (n=40 per arm). This study may support a New Drug Application (NDA), including accelerated approval.
Presented Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025: The presentation demonstrated SLS009’s ability to selectively target ASXL1-driven tumors at concentrations well below the known safety threshold. The ASXL1 mutation status could serve as a potential biomarker for response to SLS009 inhibition, which may allow the Company to further refine patient selection and improve outcomes.
Expanded Scientific Advisory Board: New members, Philip C. Amrein, MD, Alex Kentsis, MD, PhD, and Linghua Wang, MD, PhD, bring decades of expertise in cancer research, clinical oncology, and translational medicine, further strengthening the Company’s strategic guidance as it advances its pipeline.
Announced Inclusion in the Russell 3000® and Russell 2000® Indexes: The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000® Index, a subset of the Russell 3000®, measures the performance of the small-cap stocks and represents approximately
Preclinical Efficacy of SLS009 in T-Cell Prolymphocytic Leukemia (T-PLL) to be Showcased at ESMO 2025: The poster, entitled, CDK9 Inhibition Enhances Venetoclax Activity and Prolongs Survival in a T-PLL Patient-Derived Xenograft Model, will be presented during the ESMO congress to be held in Berlin, 17-21 October 2025.
Financial Results for the Second Quarter 2025:
R&D Expenses: Research and development expenses for the quarter ended June 30, 2025 were
G&A Expenses: General and administrative expenses for the second quarter of 2025 were
Net Loss: The net loss was
Cash Position: As of June 30, 2025, cash and cash equivalents totaled approximately
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS� lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,� including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,� “expect,� “anticipate,� “may,� “might,� “will,� “should,� “project,� “believe,� “estimate,� “predict,� “potential,� “intend,� or “continue� and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors� in SELLAS� Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS� forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
SELLAS LIFE SCIENCES GROUP, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share data) (Unaudited) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 3,871 | $ | 5,186 | $ | 7,076 | $ | 10,297 | ||||||||
General and administrative | 3,002 | 2,435 | 5,860 | 6,969 | ||||||||||||
Total operating expenses | 6,873 | 7,621 | 12,936 | 17,266 | ||||||||||||
Loss from operations | (6,873 | ) | (7,621 | ) | (12,936 | ) | (17,266 | ) | ||||||||
Non-operating income: | ||||||||||||||||
Interest income | 272 | 151 | 522 | 230 | ||||||||||||
Total non-operating income | 272 | 151 | 522 | 230 | ||||||||||||
Net loss | $ | (6,601 | ) | $ | (7,470 | ) | $ | (12,414 | ) | $ | (17,036 | ) | ||||
Per share information: | ||||||||||||||||
Net loss per common share, basic and diluted | $ | (0.07 | ) | $ | (0.13 | ) | $ | (0.13 | ) | $ | (0.33 | ) | ||||
Weighted-average common shares outstanding, basic and diluted | 98,558,567 | 57,630,506 | 93,189,273 | 51,221,752 |
SELLAS LIFE SCIENCES GROUP, INC. CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share and per share data) (Unaudited) | ||||||||
June 30, 2025 | December 31, 2024 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 25,297 | $ | 13,886 | ||||
Restricted cash and cash equivalents | 100 | 100 | ||||||
Prepaid expenses and other current assets | 4,050 | 2,341 | ||||||
Total current assets | 29,447 | 16,327 | ||||||
Operating lease right-of-use assets | 683 | 925 | ||||||
Goodwill | 1,914 | 1,914 | ||||||
Deposits and other assets | 261 | 266 | ||||||
Total assets | $ | 32,305 | $ | 19,432 | ||||
LIABILITIES AND STOCKHOLDERS� EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,336 | $ | 3,500 | ||||
Accrued expenses and other current liabilities | 2,083 | 5,466 | ||||||
Operating lease liabilities | 580 | 544 | ||||||
Total current liabilities | 5,999 | 9,510 | ||||||
Operating lease liabilities, non-current | 157 | 457 | ||||||
Total liabilities | 6,156 | 9,967 | ||||||
Commitments and contingencies | ||||||||
Stockholders� equity: | ||||||||
Common stock, | 10 | 7 | ||||||
Additional paid-in capital | 286,678 | 257,583 | ||||||
Accumulated deficit | (260,539 | ) | (248,125 | ) | ||||
Total stockholders� equity | 26,149 | 9,465 | ||||||
Total liabilities and stockholders� equity | $ | 32,305 | $ | 19,432 |
